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a  b  s  t  r  a  c  t
Objectives:  The  goal  of  this  study  is  to describe  hospitalization  for treatment  of Dupuytren’s  disease  in
France  between  2002  and  2009.
Methods:  A  repeated,  annual,  cross-sectional  national  survey  of public  and  private  French  hospitals  was
performed  between  2002  and 2009,  with  planned  selection  criteria  for  data extraction.  Outcomes  were
age, sex,  number  of hospitalizations,  length  of stays,  and  types  of  surgical  procedure.  Types of  surgical
procedure  included  aponeurectomy,  aponeurotomy,  transplantation  (skin  graft),  arthrolysis,  amputation,
arthrodesis,  combined  procedures.
Results:  The  selected  hospital  stays  represented  95%  to  97%  of all stays  with  Dupuytren’s  disease  coded
as  the  primary  diagnosis.  The  hospitalizations  involved  mainly  men  in  the  7th  decade.  The  mean  number
of  hospitalizations  for Dupuytren’s  disease  was 16,487,  for  between  7  and 8/10,000  total  hospitalizations
each  year.  Most  of  the  hospitalizations  for Dupuytren’s  disease  were  one-day  stays  in  private  settings.
Over  time,  the  mean  length  of  hospital  stay  signiﬁcantly  shortened  and  the  proportion  of  one-day  stays
signiﬁcantly  increased.  Aponeurectomy  was  the  most  reported  treatment.  The  distribution  of aponeurec-
tomy  of 1 ﬁnger  or ≥  2  ﬁngers  was balanced.  The  performance  of arthrolysis,  transplantation,  amputation
and  arthrodesis  was  low.
Conclusions:  Despite  of shortening  of  hospitals  stays  over  time,  hospitalization  for  surgery  for  Dupuytren’s
disease  in France  still  represents  a  meaningful  economic  burden.
Level  of evidence:  Observational  study  II.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Dupuytren’s disease is a world-wide musculoskeletal disorder
1]. It consists in progressive ﬁbrosis of the palmar aponeurosis
ecause of pathologic production and deposition of collagen [2].
he consequence is the formation of nodules and cords within
he palmar aponeurosis that can induce ﬂexion contracture of the
etacarpophalangeal and interphalangeal joints. The prevalence
f Dupuytren’s disease varies by country, age, sex and other risk
actors such as heredity, diabetes, tobacco and alcohol consump-
ion, and heavy manual work [1]. Most of the prevalence studies
ave been conducted in northwestern Europe. Two of them, each cross-sectional analysis of about 7000 people from the gen-
ral population, indicated a prevalence of 3.5% and 11% in the
nited Kingdom and Denmark, respectively [3,4]. The incidence of
∗ Corresponding author. Tel.: +33 01 49 95 63 08; fax: +33 01 49 95 86 31.
E-mail address: johann.beaudreuil@lrb.aphp.fr (J. Beaudreuil).
http://dx.doi.org/10.1016/j.otsr.2014.05.013
877-0568/© 2014 Elsevier Masson SAS. All rights reserved.Dupuytren’s disease has been estimated at about 34/100,000 males
in England [5].
Treatment of Dupuytren’s disease includes percutaneous and
open surgical procedures [2,6]. Percutaneous options are needle
aponeurotomy and collagenase injection that are non-surgical pro-
cedures. According to their advocates, these percutaneous methods
would be applicable for early and advanced Dupuytren’s disease
and allow for immediate resumption of regular activities. Needle
aponeurotomy is an ambulatory treatment developed in the 1970s
[7]. Collagenase injection has more recently been proposed for
Dupuytren’s disease with ﬂexion contracture between 20◦ and 100◦
[8–10]. Open surgery mainly includes aponeurectomy and dermo-
aponeurectomy. It remains the most recommended treatment for
Dupuytren’s disease and probably the most used in clinical practice
[11,12]. Open surgery for Dupuytren’s disease may therefore repre-
sent a high economic burden. Because it is performed in a hospital
setting, national hospital databases are suitable for assessing sur-
gical practice for Dupuytren’s disease. However, studies of the
practice of Dupuytren’s surgery are uncommon [13–15]. In a
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Table 1
Hospitalizations for Dupuytren’s disease from 2002 to 2009 in France.
Hospitalization characteristics 2002 2003 2004 2005 2006 2007 2008 2009
Hospitalizations for
Dupuytren’s disease, no.
15,846 16,725 15,096 16,427 16,824 16,207 17,079 17,696
Hospitalizations for
Dupuytren’s disease/10,000
7.52 7.63 6.83 7.11 7.07 6.94 7.03 7.28
Private hospitalizations for
Dupuytren’s disease, no. (%)
12,491 (78.8) 13,136 (78.5) 11,699 (77.5) 12,893 (78.5) 13,068 (77.7) 12,690 (78.3) 13,021 (76.2) 13,331 (75.3)
Length  of stay, mean (SD)b 2.3 (3.0) 2.2 (2.0) 2.1 (2.4) 2.1 (2.6) 2.0 (1.4) 1.9 (1.5) 1.8 (1.2) 1.8 (1.3)
One-day stays, no. (%)b 8260 (52.1) 9056 (54.1) 8399 (55.6) 9406 (57.3) 10,040 (59.7) 10,269 (63.4) 11,150 (65.3) 12,095 (68.3)
Patient  characteristics from
hospitalization data
Men, no. (%) 13,000 (82.0) 13,762 (82.3) 12,392 (82.1) 13,275 (80.8) 13,633 (81.0) 13,201 (80.8) 13,716 (80.3) 14,228 (80.4)
Age,  mean (SD) 60.9 (11.4) 61.1 (11.1) 61.3 (11.2) 61.6 (11.1) 61.8 (11.1) 61.8 (11.1) 62.0 (11.1) 66.8 (7.1)
Treatment from hospitalization
data
Aponeurectomy, no. (%)a 14,178 (87.7) 14,803 (87.2) 13,013 (85.2) 14,416 (86.8) 15,091 (88.8) 14,707 (90.0) 15,300 (88.8) 15,719 (88.8)
































a Number of procedures coded as aponeurectomy divided by all procedures relat
b Signiﬁcant difference over time, P < 0.0001.
revious study, it was found that open surgery for Dupuytren’s
isease represented about 15,000 hospitalizations and 14 million
uros in France in 2001.
Because of the global trend in increased number of hospital-
zations on one hand [16] and the development of percutaneous
mbulatory treatments for Dupuytren’s disease on the other [7–10],
nowledge about the evolution of hospitalizations for the dis-
ase is of interest. Here, we aimed to analyze the evolution of
ospitalizations for Dupuytren’s disease from 2002 to 2009 in
rance.
. Methods
The main objective of the study is therefore to describe and to
nalyze the evolution of hospitalizations for Dupuytren’s disease
rom 2002 to 2009 in France.
. Study design
This study was a repeated, annual, cross-sectional national sur-
ey from 2002 to 2009 with planned selection criteria for data
xtraction.
. French National Hospital Database
The French National Hospital Database includes data on all hos-
italizations for acute and rehabilitation care in public and private
ettings. These data comprise administrative information such as
ex, age, and type of hospital, as well as medical information,
ncluding diagnosis and procedures encoded by the International
lassiﬁcation of Diseases – 10 (ICD-10) codes and the catalogue of
edical devices (until 2004–2005) or the French common classiﬁ-
ation of medical procedures (since 2004–2005). According to the
rench law, hospitals must keep complete and accurate databases
o receive funding.. Data extraction
We  used the acute care data for 2002 to 2009 from the
atabases. The selection criteria for hospital stays were age ≥ 20
ears, Dupuytren’s disease as primary diagnosis, and procedure
ncoded as aponeurotomy or aponeurectomy.the treatment of Dupuytren’s disease.
6. Outcomes
For characteristics of hospitalizations, were reported total and
private hospitalizations, length of hospital stay and one-day stays,
using number, percentage, mean and standard deviation (SD) as
appropriate. For characteristics of patients, we  present age and
male sex. Aponeurectomy data are presented as number and per-
centage for both aponeurectomy and aponeurotomy, from 2002
to 2009. From 2006 to 2009, the French common classiﬁcation of
medical procedures allowed for analyzing more procedures than
aponeurectomy and aponeurotomy, including arthrolysis, trans-
plantation (skin grafts), amputation and arthrodesis, which were
expressed as a number. Number of hospitalization for surgery for
Dupuytyren’s disease and number and percentage of hospitaliza-
tions for aponeurectomy were primary outcomes. Other criteria
were secondary outcomes.
6.1. Statistical analysis
We  performed descriptive statistical analysis of data for each
year from 2002 to 2009. We  analyzed evolution over time for length
of hospital stay and one-day stays by Chi-square test and ANOVA
and R v2.9.0 [2009–04–17] for Windows (Insightful Corp., Seattle,
WA). A two-sided P < 0.05 was considered statistically signiﬁcant.
7. Results
The selected data represent 95% to 97% of all hospital stays for
Dupuytren’s disease coded as the primary diagnosis from 2002 to
2009. The remaining 3 to 5% are due to hospital stays without
aponeurectomy or aponeurotomy as procedure.
The characteristics of the hospitalizations for Dupuytren’s dis-
ease from 2002 to 2009 are in Table 1. The hospitalizations involved
mainly men  (80–82%) in the 7th decade. The mean number of hospi-
talizations for Dupuytren’s disease was  16,487, for 7 to 8/10,000 of
total hospitalizations each year. Whatever the year, most of the hos-
pitalizations for Dupuytren’s disease were one-day stays in private
settings. Over time, the lengths of stay signiﬁcantly shortened and
the proportion of one-day stays signiﬁcantly increased (52–68%).
Aponeurectomy was  the most reported treatment (85–90%).The details of the therapeutic management from 2006 to 2009
are in Table 2. Aponeurectomy of 1 ﬁnger (7035–7858 hospi-
talizations each year) or ≥ 2 ﬁngers (7610–8070) was  equally
performed. The sum of both procedures gave slightly higher values
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Table  2
Number of therapeutic procedures during hospitalization for Dupuytren’s disease from 2006 to 2009 in France.
2006 2007 2008 2009
Aponeurectomy 15,091 14,707 15,300 15,719
1  ﬁnger 7035 7113 7531 7858
≥  2 ﬁngers 8070 7610 7777 7872
Aponeurotomy 1855 1592 1891 2087
Percutaneous approach 727 589 723 877
Open  approach 1171 1047 1204 1264
Arthrolysis 617 699 767 874
Transplant ation 429 406 462 502
Amputation 41 46 42 45
Arthrodesis 28 29 42 51
Aponeurectomy + arthrolysis 577 661 737 842
Aponeurectomy + transplantation 417 392 441 490













































sOther  53 
ata extracted from the French National Database with use of codes from the Interna
han the number of treatments recorded as aponeurectomy, which
uggests that some patients received treatment for a bilateral con-
ition during the same stay. Procedures other than aponeurectomy
ere exceptionally performed as unique treatment. Aponeurotomy
anked second (1592–2087). Arthrolysis (617–874) and transplan-
ation (406–502) were performed more than were amputation
41–46) or arthrodesis (28–51). All these procedures were mainly
ombined with aponeurectomy. The number of combined proce-
ures remained low as compared with aponeurectomy as a unique
reatment.
. Discussion
We  provide original data on hospitalizations for Dupuytren’s
isease on a national basis in France between 2002 and 2009. Hos-
italizations for Dupuytren’s disease represented 15,000–18,000
tays of a mean of 2 days, with most in private hospitals. In
ccordance with epidemiological studies, most patients were male,
nd most were in their 60s and 70s [1]. These values are close
o those obtained in 2001 [14]. This study reinforces that fact
hat aponeurectomy is the most frequently performed technique
uring hospitalization for Dupuytren’s disease, with a balanced
roportion of treatments of 1 ﬁnger and ≥ 2 ﬁngers. Combinations
ncluding transplantation, arthrolysis, arthrodesis and amputation
eemed uncommon. The characteristics of the hospitalizations for
upuytren’s disease appeared constant over the study period, with
he exception of length of stay, which was signiﬁcantly shortened
ver time.
The selection criteria we used for the extraction were planned
nd accounted for 95% to 97% of hospital stays with Dupuytren’s
isease as the primary diagnosis. Therefore, our data from the
rench National Hospital Database are representative of surgi-
al practice for inpatients with Dupuytren’s disease in France. A
ecent database analysis in England allows direct comparison [15].
his study analyzed 86% of admissions for Dupuytren’s disease
etween 2003 and 2008. It reported around 13,000 admissions for
upuytren’s disease each year, increasing number of day cases on
he study period and aponeurectomy as the main procedure, that is
n accordance with our results. The rate of private admissions and
he number of treated ﬁnger for each admission were not reported.
igh involvement of private hospitals we found may  be due to
he income generated. Data from national surveys of hospitaliza-
ion have been reported for other rheumatic diseases in France
n the last decade [17,18]. Interestingly, hip fracture considered
o have high economic burden was responsible for about 15,000
ospital admissions each year from 2002 to 2008 for men  and
0,000 for women [17]. Primary joint replacement for coxarthro-
is and gonarthrosis represented about 70,000 and 40,000 hospital58 82 98
l Classiﬁcation of Diseases and French common classiﬁcation of medical procedures.
admissions in 2001 in France [18]. The annual number of stays we
found in the present study therefore suggests a meaningful eco-
nomic burden of hospitalization and open surgery for Dupuytren’s
disease.
We chose aponeurotomy and aponeurectomy as criteria for
selecting the hospital stays because both are considered open-
surgery techniques [11]. Aponeurotomy can also be performed
percutaneously with a needle in a medical outpatient setting
[7]. Aponeurectomy is easily identiﬁable by a speciﬁc code in
the catalogue of medical devices in effect up to 2004–2005
and in the French common classiﬁcation of medical procedures
after this period. Two types of aponeurotomy are deﬁned in
the French common classiﬁcation of medical procedures. They
are open and percutaneous techniques without any mention
of a blade or a needle. Aponeurotomy recorded as an open
approach in the classiﬁcation is indisputably surgery. However,
whether percutaneous aponeurotomy is surgery in our study
remains unknown. Needle aponeurotomy is indeed a non-surgical
approach developed by rheumatologists and suitable for an out-
patient medical setting [7,19]. Aponeurotomy by surgeons with
a blade has also been proposed. Unfortunately, we were unable
to distinguish needle aponeurotomy from aponeurotomy with
a blade in the French common classiﬁcation of medical proce-
dures. Furthermore, the catalogue of medical devices in effect
until 2004–2005, mentions only percutaneous aponeurotomy and
not open aponeurotomy. Whatever the technique, the perfor-
mance of aponeurotomy remained marginal as compared with
aponeurectomy, which represented more than 85% hospitaliza-
tions from 2002 to 2009. Considering aponeurectomy, open and
percutaneous aponeurotomy from 2006 to 2009, aponeurectomy
and open aponeurotomy that correspond to surgical management
of Dupuytren’s disease accounted for more than 95% treatments.
Our study has some limitations. The data recording was anony-
mous, so we could not check reliability by reviewing medical charts.
However, each hospital performs a monthly internal control of cod-
ing for the French National Hospital Database, and physicians of
the national medical insurance service perform a yearly external
control. Our results, based on data from a French national survey,
may not be representative of hospitalizations for Dupuytren’s dis-
ease in other countries. Nonetheless, they are in accordance with
a previous review of surgical practice for Dupuytren’s disease in
the United Kingdom [13] and with recommendations elaborated
under the assistance of the American Society of Plastic Surgeons
[12]. Characteristics of our population also agree with those from
previous epidemiological reports [1]. So, our results may  be reliable.
The French National Hospital Database does not allow for describ-
ing ambulatory treatment of Dupuytren’s disease. Therefore, our
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eans for the management of the disease. Describing and moni-
oring the total spectrum of care for Dupuytren’s disease, including
npatient and outpatient settings, remain crucial for health eco-
omic decision makers. Finally, due to the characteristics of the
atabase we used, our study did not include any effectiveness out-
ome of the procedures.
Half of the recorded aponeurectomies involved 1 ﬁnger only.
he number of combined treatments suggesting complex forms
f Dupuytren’s disease was low. Indeed, transplantation is usually
ndicated with aponeurectomy in case of recurrence, arthrolysis
f joint stiffness, and arthrodesis and amputation with severe or
ecurring Dupuytren’s disease [12,13]. About half of the hospital-
zations may  have involved patients with non-complex form of
upuytren’s disease. The mean individual cost for hospital manage-
ent of Dupuytren’s disease has been reported to be 707 and 1795
uros for private and public care settings, respectively, on the basis
f the 2005 hospital tariff for France [14]. These data correspond to
 1-year cost of 14,179,988 Euros. The high cost of management of
upuytren’s contracture fully justiﬁes, in addition to the decision
riteria usually assessed (functional gene, anatomical lesions, ben-
ﬁt/risk relationship), taking into account the medico-economic
mpact in terms of cost of hospitalization (partly controlled by the
ne-day hospitalization) and especially duration of work stoppage
hich may  extend over several months.
In conclusion, despite of shortening of hospital stays over time,
upuytren’s disease still represents a meaningful number of hos-
italizations each year in France, and therefore a meaningful
conomic burden. Management during hospitalization is surgery,
ainly aponeurectomy, involving early and advanced stages of
upuytren’s disease.
isclosure of interest
I, Johann Beaudreuil, declare speaking fees less than 1000 euros
rom Pﬁzer and a previous scientiﬁc collaboration with the same
rganisation; no other ﬁnancial relationships with any organi-
ations that might have an interest in the submitted work; no
upport from any organisation for the submitted work; no other
elationships or activities that could appear to have inﬂuenced the
ubmitted work. Milka Maravic, Sandra Lasbleiz and Eric Roulot,
y co-authors, declare no support from any organisation for the
ubmitted work; no ﬁnancial relationships with any organisa-
ions that might have an interest in the submitted work; no other
[: Surgery & Research 100 (2014) 589–592
relationships or activities that could appear to have inﬂuenced the
submitted work.
References
[1] Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of
Dupuytren’s disease incidence and prevalence rates in relation to etiology.
Hand 2009;4(3):256–69.
[2] Shih B, Bayat A. Scientiﬁc understanding and clinical management of Dupuytren
disease. Nat Rev Rheumatol 2010;6(12):715–26.
[3] Early P. Population studies in Dupuytren’s contracture. J Bone Joint Surg Br
1962;44(3):602–13.
[4] Godtfredsen NS, Lucht H, Prescott E, Sorensen TI, Gronback M.  A prospective
study linked both alcohol and tobacco to Dupuytren’s disease. J Clin Epidemiol
2004;57(8):858–63.
[5] Khan AA, Rider OJ, Jayadev CU, Heras-Palou C, Giele H,  Goldacre M.  The role of
manual occupation in the aetiology of Dupuytren’s disease in men in England
Wales. J Hand Surg Br 2004;29(1):12–4.
[6] National Institute For Clinical Excellence. IPG043 needle fasciotomy for
Dupuytren’s contracture - guidance; 2004 [Accessed May  26, 2010]
http://guidance.nice.org.uk/IPG43/Guidance/pdf/English
[7] Beaudreuil J, Lellouche H, Orcel P, Bardin T. Needle aponeurotomy in
Dupuytren’s disease. Joint Bone Spine 2012;79(1):13–6.
[8] Badalamente MA,  Hurst LC. Efﬁcacy and safety of injectable mixed collagen-
ase  subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am
2007;32(6):767–74.
[9] Hurst LC, Badalamente MA,  Hentz VR, Hotchkiss RN,  Kaplan FT, Meals RA, et al.
Injectable collagenase clostridium hystolyticum for Dupuytren’s contracture.
N  Engl J Med  2009;361(10):968–79.
10] Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagen-
ase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s
disease. J Hand Surg Am 2010;35(12):2027–38.
11] Townley WA,  Baker R, Sheppard N, Grobbelaar AO. Dupuytren’s contracture
unfolded. BMJ  2006;332(7538):397–400.
12] Brandt KE. An evidence-based approach to Dupuytren’s contracture. Plast
Reconstr Surg 2010;126(6):2210–5.
13] Au-Yong IT, Wildin CJ, Dias JJ, Page RE. A review of common practice in
Dupuytren surgery. Tech Hand Up Extrem Surg 2005;9(4):178–87.
14] Maravic M,  Landais P. Dupuytren’s disease in France – 1831 to 2001 – from
description to economic burden. J Hand Surg Br 2005;30(5):484–7.
15] Gerber RA, Perry R, Thompson R, Bainbridge C. Dupuytren’s contracture: a
retrospective database analysis to assess clinical management and costs in
England. BMC Musculoskelet Disord 2011;12:73.
16] Hall MJ,  DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National
hospital discharge survey: 2007 summary. Natl Health Stat Rep 2010;26(29),
1-20,24.
17] Maravic M, Taupin P, Landais P, Roux C. Change in hip fracture incidence over
the last 6 years. Osteoporos Int 2011;22(3):797–801.
18] Maravic M,  Landais P. Usefulness of a national hospital database to evaluate
the burden of primary joint replacement for coxarthrosis and gonarthrosis in
patients aged over 40 years. Osteoarthritis Cartilage 2006;14(6):612–5.
19] Beaudreuil J, Lermusiaux JL, Teyssedou JP, Lahalle S, Lasbleiz S, Bernabé B,
et  al. Multi-needle aponeurotomy for advanced Dupuytren’s disease: pre-
liminary results of safety and efﬁcacy (MNA 1 Study). Joint Bone Spine
2011;78(6):625–8.
